Risk stratification and early detection of polyps are provided by diagnostic markers, such as: insulin like growth factor binding protein 2 (IGFBP2; elevated levels in plasma and serum of CRC patients) [12,14], telomerase (an enzyme responsible for synthesizing DNA from chromosome ends for which an increase in activity was noticed for 90% of colorectal tumors) [17], and pyruvate kinase M2 (PKM2; a glycolytic pyruvate kinase isoenzyme increased in the stool of CRC subjects) [16]. This evidence concerns the gene IGFBP2 and colorectal neoplasm.